Alexion: Positive Phase 3 Extension Data at European Hematology Association

• ULTOMIRIS demonstrated consistent efficacy and safety through 52 weeks, with no cases of breakthrough hemolysis (BTH) associated with incomplete C5 complement inhibition
• Nearly all surveyed patients preferred ULTOMIRIS over SOLIRIS^® (eculizumab)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the presentation of new data demonstrating that ULTOMIRIS^® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, provided consistent efficacy and safety through 52 weeks in the extension¹ of the Phase 3 study of ULTOMIRIS and SOLIRIS^® (eculizumab) in complement inhibitor-naïve, adult patients with paroxysmal nocturnal hemoglobinuria (PNH).² Sustained efficacy of ULTOMIRIS was observed on the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels and the secondary endpoints of LDH level reduction and breakthrough hemolysis (BTH). In an additional sub-study, nearly all patients preferred ULTOMIRIS over SOLIRIS.³ The data will be presented at the Annual Congress of the European Hematology Association (EHA), taking place June 13-19, 2019 in Amsterdam, Netherlands.

https://www.biospace.com/article/releases/positive-phase-3-extension-data-for-ultomiris-ravulizumab-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-presented-at-european-hematology-association-eha-congress/